A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Celgene
Study ID
NCT06988488
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elranatamab — DRUG
    Specified dose on specified days
  • Mezigdomide — DRUG
    Specified dose on specified days
  • Dexamethasone — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

Key Dates

Start date
Oct 7, 2025
Status verified
May 2026
Primary completion
May 31, 2027
Completion
Jun 3, 2027

Study Design

Enrollment
62 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1
  • Experimental: Phase 2

Primary Outcome Measure

Number of participants with Adverse Events (AEs) [ Time Frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (4)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
Luciano Costa, Site 0001
205-934-9695
Yale New Haven Hospital-Smilow Cancer CenterNew HavenConnecticut06510
Noffar Bar, Site 0029
000-000-0000
Hackensack University Medical CenterHackensackNew Jersey07601
David Siegel, Site 0028
551-996-8704
University of Texas MD Anderson Cancer CenterHoustonTexas77030
Jing Christine Ye, Site 0005
734-232-0744

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Alabama at Birmingham· Birmingham, ALYale New Haven Hospital-Smilow Cancer Center· New Haven, CTHackensack University Medical Center· Hackensack, NJUniversity of Texas MD Anderson Cancer Center· Houston, TX

Related Studies